Targeting Thyroid Cancer: From Biology to Therapeutic Strategies
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (15 January 2024) | Viewed by 5036
Special Issue Editors
2. i3S—Instituto de Investigação e Inovação em Saúde, Cancer Signaling and Metabolism Group, Porto, Portugal
3. IPATIMUP—Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal
Interests: thyroid cancer; neuroendocrine tumors; oncobiology
2. IPATIMUP – Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal
3. Department of Pathology – Faculty of Medicine of the University of Porto, Porto, Portugal
Interests: oncobiology; cancer biomarkers; drug resistance; anticancer therapeutic strategies
Special Issues, Collections and Topics in MDPI journals
2. IPATIMUP – Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal
Interests: metabolism; reactive oxygen species; apoptosis; oncobiology; mitochondrial biology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Thyroid cancer-TC represents the most common endocrine malignancy (being the fifth cause of cancer in women), with its incidence rapidly increasing globally. Mostly, thyroid cancer patients are cured with surgery followed by radioactive iodine (RAI). Still, in 10-15% of the patients’ disease persists or recurs. Of these, 60% do not respond to treatment with RAI. Following RAI-refractory (RAI-R) disease, the outcome of those patients drops significantly, with 10-year survival rate of less than 10% and the mean life expectancy of 3–5 years.
The advances in targeted therapies, in particular tyrosine kinase inhibitors-TKI (targeting molecules/signaling pathways involved in TC pathogenesis) brought hope to RAI-R patients, for whom no therapies were available. This is particularly true for undifferentiated thyroid cancer where new genetic targets (as ALK or TRK) have demonstrated excellent responses, but it is also true in advanced follicular cell cancer and in medullary thyroid cancer.
However, and despite initial response, resistance can develop, with disease progression and patient death. TC complex heterogeneity is a major hurdle, going much beyond the simple action of known oncogenes and/or tumor suppressor genes. Indeed, it is becoming increasingly evident that genetic and epigenetic alterations occur during progression/metastasis (some of which driven by treatment selective pressure). Moreover, changes in tumor interactions with its microenvironment/immune cells further contribute to TC progression, aggressiveness and/or response to therapy.
This special issue will focus on the recent findings on TC research field, from its underlying biology to the players/mechanism involved in TC heterogeneity and response to therapy.
Your contributions, either through original research articles or review papers, will be relevant to further evolve in this field.
Prof. Dr. Paula Soares
Dr. Raquel T. Lima
Dr. Marcelo Correia
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- thyroid cancer
- radio iodine therapy
- therapy resistance
- targeted therapies
- tumor heterogeneity
- signaling pathways
- metastasis
- tyrosine kinase receptors
- Tyrosine Kinase inhibitors (TKI)
- tumor microenvironment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
